Difficulty: Medium
Average Score: 95%
Practice
Of the following, the MOST appropriate initial therapy for a 12-year-old female adolescent with mild arthritis and a faint malar rash is
Correct answer
C
Rationale
In this scenario, the most appropriate initial therapy for a 12-year-old female adolescent with mild arthritis and a faint malar rash is option C) hydroxychloroquine.
Hydroxychloroquine is the preferred initial treatment in pediatric patients with mild arthritis and a faint malar rash, as seen in conditions like juvenile idiopathic arthritis with possible early signs of systemic lupus erythematosus. It is well-tolerated and has a favorable safety profile in children. Hydroxychloroquine helps in managing arthritis symptoms and can also improve the skin manifestations like the malar rash.
Option A) steroids are not typically the initial choice for mild arthritis and malar rash in this age group due to their potential side effects and long-term risks, especially in children.
Systemic methotrexate (option B) and cyclophosphamide (option D) are more potent immunosuppressants that are usually reserved for more severe cases of arthritis or lupus with organ involvement, not as first-line treatments for mild symptoms in a 12-year-old.
Educationally, understanding the rationale behind selecting appropriate initial therapy based on the severity of symptoms, safety profile in pediatric patients, and the specific characteristics of the conditions being treated is crucial for healthcare providers managing pediatric patients with rheumatologic conditions. It highlights the importance of individualized treatment plans in pediatric care to optimize outcomes while minimizing potential risks and side effects.
Hydroxychloroquine is the preferred initial treatment in pediatric patients with mild arthritis and a faint malar rash, as seen in conditions like juvenile idiopathic arthritis with possible early signs of systemic lupus erythematosus. It is well-tolerated and has a favorable safety profile in children. Hydroxychloroquine helps in managing arthritis symptoms and can also improve the skin manifestations like the malar rash.
Option A) steroids are not typically the initial choice for mild arthritis and malar rash in this age group due to their potential side effects and long-term risks, especially in children.
Systemic methotrexate (option B) and cyclophosphamide (option D) are more potent immunosuppressants that are usually reserved for more severe cases of arthritis or lupus with organ involvement, not as first-line treatments for mild symptoms in a 12-year-old.
Educationally, understanding the rationale behind selecting appropriate initial therapy based on the severity of symptoms, safety profile in pediatric patients, and the specific characteristics of the conditions being treated is crucial for healthcare providers managing pediatric patients with rheumatologic conditions. It highlights the importance of individualized treatment plans in pediatric care to optimize outcomes while minimizing potential risks and side effects.